PanTher Therapeutics Receives FDA Clearance of IND Application for Phase 1b Study of PTM-101 for the Localized Treatment of Pancreatic Cancer August 13, 2024-PanTher Therapeutics
PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment September 1, 2022-PanTher Therapeutics
PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent May 31, 2022-PanTher Therapeutics
PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer October 15, 2021-PanTher Therapeutics
PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia; Announces Appointment of Chief Medical Officer; Establishes Clinical Advisory Board August 4, 2021-PanTher Therapeutics
PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer June 17, 2021-PanTher Therapeutics
